MTN-038
Overview of Data Collection and Management

Amanda Brown, Lead CDM
SCHARP
Seattle, WA
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
Outline

• What we will not cover
  – CASI
  – Rave manual
  – Query management
  – CCGs
  – Atlas
  – SSPs
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
Rave/PTID Basics

- “Add Subject” generates a PTID
Rave/PTID Basics

- PTID structure

<table>
<thead>
<tr>
<th>CRS Name</th>
<th>DAIDS ID</th>
<th>Rave ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birmingham</td>
<td>31788</td>
<td>821</td>
</tr>
<tr>
<td>Pittsburgh</td>
<td>1001</td>
<td>702</td>
</tr>
<tr>
<td>Bridge (SF)</td>
<td>30305</td>
<td>764</td>
</tr>
</tbody>
</table>

- Unique 9 digit identifier

XXX-YYYYYZ

Rave ID  Ppt ID + check digit
Rave/PTID Basics

- The PTID-Name Linkage Log must be completed in real time. It is considered a source document for assigning PTIDs to participants.
Rave/PTID Basics

- Direct data entry is strongly recommended. Site Data Management SOP should address data that will not be direct-entered.
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
Randomization

• Approx. 48 participants will be randomized in a 2:1 ratio to either 1.4 g TFV IVR or to a placebo IVR.

• The timing of biopsies will also be randomly assigned.
  – Both of these randomizations take place within the database.

• In addition, approx. 24 participants will be randomly selected for In-Depth Interviews (IDIs).

• The randomization schemes will be generated and maintained by the MTN SDMC and specified in the MTN-038 SSP manual.
Randomization

- Participants will be randomized to In-Depth Interviews (IDIs) outside of Medidata Balance.
  - MTN SDMC will provide separate IDI randomization lists to each site.
  - After treatment group and biopsy schedule randomization in Balance, use the Randomization ID to find the IDI group on the IDI randomization list.
Randomization

- Document IDI Randomization on Enrollment CRF
  - Randomization ID can be found on the Randomization CRF in the Enrollment visit

- Document IDI in Enrollment CRF in Enrollment Visit
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
Form Population Dynamics

- When you assign a PTID, all forms for Screening and Enrollment are automatically generated within a participant’s visit folder, including Ongoing Logs.
Form Population Dynamics

• In order to populate the remaining visit folders for each participant:

  1) In the V1 - Screening folder, on the Inclusion/Exclusion Criteria form, click “Yes”, in response to “Did the participant meet all eligibility criteria?”
Form Population Dynamics

- In order to populate the remaining visit folders for each participant:
  2) ... and in the Enrollment folder, on the Randomization form, click “yes” on “Is the participant ready to be randomized?” Click “save”, and all the remaining visit folders will populate.
Form Population Dynamics

• Regardless of whether or not a participant ultimately enrolls, please complete the Inclusion Exclusion Criteria and Demographics forms in the Screening folder for everyone who signs a consent form.
Form Population Dynamics

• For every follow-up visit (V3-10), the “Follow-Up YN” form needs to be completed in order to populate the remainder of the forms for that visit.

• It is now standard for YN CRFs to populate their respective CRFs
  – this is a change! – used to have summary forms, now you need to fill out the YN form first

• Once a particular YN CRF has been completed with “Yes”, the respective CRF will populate for subsequent visits
The Demographics CRF you complete at Screening uses calculated age and other data to populate the lab module in Medidata.

In Chemistry and Hematology CRFs, select lab FIRST:

Select your local lab first so that laboratory reference ranges can auto populate for each analyte being entered on the form.
Form Population Dynamics

- Screening Forms
  - No AEs expected at Screening or Enrollment
Form Population Dynamics

• To Add Pregnancy & Interim visits
  – Find the “Add Event” dropdown menu
  – Menu located at the bottom of the ppt “home” page
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
MTN-038-specific forms

• PK Endpoints (Primary)
  – TFV concentrations in plasma
  – TFV concentrations in CVF
  – TFV concentrations in rectal fluid
  – TFV and TFV-DP concentrations in cervical tissue
  – Particular attention to timed specimen CRFs
    • Timed cervical specimen storage at enrollment (v2.0) and v9.0
    • Timed specimen storage at PUEV/v9 when ring is removed
    • Timed versions will supplant the “normal” forms
MTN-038-specific forms

• Safety Endpoints (Primary)
  – “The proportion of participants with Grade 2 or higher genitourinary adverse event”
  – “The proportion of participants with Grade 3 or higher adverse event”
MTN-038-specific forms

• Secondary Endpoints
  – Frequency of study IVR removal/expulsions
  – IVR use initiation and persistence
  – Degree to which study participants liked or disliked using the IVR
MTN-038-specific forms

- Adverse Event (AE) Data
  - Report only one diagnosis, symptom or sign per page
    - Record unifying diagnosis whenever possible
  - Avoid using abbreviations
  - Review for correct spelling
    - Variations in spelling can lead to differences in AE coding, so similar AEs will appear differently in AE safety reports
  - Do not report surgeries as AEs (these are treatments)
MTN-038-specific forms

- Adverse Event (AE) Data
  - Report ASAP, no later than 3 days following awareness
  - severity grading per usual
  - relationship to study product per usual
  - Action taken w/ study product per usual
  - SAE or EAE reporting per usual
MTN-038-specific forms

- **Visit Windows**

- All enrollment procedures must occur on the same day.
- The participant’s menstrual cycle must be considered when scheduling Visit 2-Enrollment (Day 0). Ideally, no bleeding should occur within the first 7 days of product use, e.g., Study Visits 2-4 (Days 0, 1, and 7).
- IVR provided at Visit 2, and collected at Visit 9.
- Participants will be randomized to provide cervical tissue samples at either Visits 5 and 8 (Days 14 and 56) or at Visits 6 and 9 (Days 28 and 91).
MTN-038-specific forms

- Visit Windows

<table>
<thead>
<tr>
<th>Visit</th>
<th>Visit Code</th>
<th>Target Day</th>
<th>Window Opens</th>
<th>Window Closes</th>
<th>Visit Window Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening</td>
<td>1.0</td>
<td>NA</td>
<td>≤ 45 days prior to Enrollment</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Visit 2 - Enrollment (Day 0)</td>
<td>2.0</td>
<td>0</td>
<td>NA</td>
<td>45 days after Screening Visit</td>
<td>45 days</td>
</tr>
<tr>
<td>Visit 3 - Day 1</td>
<td>3.0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1 day (Target only)</td>
</tr>
<tr>
<td>Visit 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 7/Week 1</td>
<td>4.0</td>
<td>7</td>
<td>6</td>
<td>8</td>
<td>3 days (Target +/- 1)</td>
</tr>
<tr>
<td>Visit 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 14/Week 2</td>
<td>5.0</td>
<td>14</td>
<td>12</td>
<td>16</td>
<td>5 days (Target +/- 2)</td>
</tr>
<tr>
<td>Visit 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 28/Week 4</td>
<td>6.0</td>
<td>28</td>
<td>25</td>
<td>31</td>
<td>7 days (Target +/- 3)</td>
</tr>
<tr>
<td>Visit 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 42/Week 6</td>
<td>7.0</td>
<td>42</td>
<td>39</td>
<td>45</td>
<td>7 days (Target +/- 3)</td>
</tr>
<tr>
<td>Visit 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 56/Week 8</td>
<td>8.0</td>
<td>56</td>
<td>53</td>
<td>59</td>
<td>7 days (Target +/- 3)</td>
</tr>
<tr>
<td>Visit 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 91/Week 13</td>
<td>9.0</td>
<td>91</td>
<td>89</td>
<td>93</td>
<td>5 days (Target +/- 2)</td>
</tr>
<tr>
<td>Visit 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 92/Final Contact</td>
<td>10.0</td>
<td>92</td>
<td>24 - 72 hours after PUEV (Visit 9)</td>
<td>3 days (Target + 2)</td>
<td></td>
</tr>
</tbody>
</table>
MTN-038-specific forms

- "Local Labs" CRFs changed to CHEM and HEME
MTN-038-specific forms

Split Visits

- A visit is a split visit when the required visit procedures are split (done) over 2 or more days
- The days must all fall within allowable visit window; any required procedures not done within allowable window are missed
- For split visits, only 1 Follow-up Visit Summary eCRF is completed, and the Visit Date on this CRF is the date of the first part of the split visit
  - All CRFs completed for the split visit within the applicable study visit folder (e.g., CRFs completed for a split Visit 6 across Days 27 and 28 would all have visit code 6.0)
MTN-038-specific forms

Interim Visits

• Visits that take place between scheduled visits
  • Additional study procedures and/or data collection conducted outside of what is specified in protocol for required study visit (Example: Report of new AE, issue with study product, etc.)
  • Required study visit procedures conducted outside visit window, either to make up certain procedures from missed visit or conduct Visit 9 Early Termination Visit procedures due to early product discontinuation

• All interim contacts (e.g., phone calls and/or clinic visits) will be properly documented in study files and on applicable CRFs
MTN-038-specific forms

Missed Visits

• A visit is missed when:
  – No part of a visit is conducted within the allowable visit window, OR,
  – A visit does not have a window, and the participant cannot come in on target day.
    • For 038, the visit that meets this definition is Visit 3.

• Missed visits are not made up. Rather, sites should make every attempt to retain participants at future visits.
MTN-038-specific forms

If a participant does miss a visit:

• Document in the database using the Missed Visit CRF
• The Missed Visit form will let SCHARP know not to expect any other forms for that participant at that study visit (with the exception of the Follow-up Yes/No CRF).
• The Missed Visit CRF is completed in lieu of a Protocol Deviations Log CRF
Outline

• What we will cover
  – Rave/PTID basics
  – Randomization
  – Form population dynamics
  – MTN038-specific forms
  – Where to find more information
Where to find more information

- CRF Completion Guidelines (CCGs) to aid in form completion will be available on the MTN-038 ATLAS webpage
- Help text available on select items within Rave to provide key guidance on form completion
- Site Specific Procedures (SSPs) will also provide data-related guidance.
Where to find more information

• Last Day to Enroll calendar tool
  – *Will* be available on study website
  – [https://mtnstopshiv.org/research/studies/mtn-038](https://mtnstopshiv.org/research/studies/mtn-038)
  – Example from MTN 036
Where to find more information

- Example from MTN034
### MTN-034 - Calculation of Last Possible Day to Enroll

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>Screening Visit Date:</strong> Date Screening Consent marked or signed</td>
<td><strong>Monday, January 8, 2018</strong> <strong>Enter as dd-mmm-yy</strong></td>
<td>Instructions:</td>
</tr>
<tr>
<td>2</td>
<td><strong>Date participant initiates effective method of contraception:</strong></td>
<td><strong>Wednesday, January 10, 2018</strong> <strong>Enter as dd-mmm-yy</strong></td>
<td>1. Enter Screening visit date in order to generate a protocol for the participant’s enrolment in the REACH project. Enter as dd-mmm-yy.</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>2. Enter the date participant initiates an effective method of contraception to generate the first possible enrolment date. Ensure that the participant meets all eligibility criteria #9. Do not use the date participant prior enrolment to generate the first possible enrolment date.</td>
</tr>
<tr>
<td>4</td>
<td><strong>First possible Enrolment date based on initiation of effective method of contraception:</strong></td>
<td><strong>Sunday, March 11, 2018</strong> <strong>Shown as dd-mmm-yy</strong></td>
<td>Per inclusion criteria, participants may only use an effective method of contraception for a period of 3 months prior to enrolment.</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td><strong>Last Day to Enroll:</strong></td>
<td><strong>Monday, March 19, 2018</strong></td>
<td></td>
</tr>
</tbody>
</table>
Where to find more information

• For non-protocol specific overviews:
  – https://mtnstopshiv.org/research/studies/mtn-020/study-implementation-materials/clinical-research-training

• For Medidata RAVE:
  – www.imedidata.com

• For help with ATLAS:
  – https://atlas.scharp.org/
Questions?

Amanda Brown, CDM
abrown@scharp.org